REFERENCES
1. DePinho RA. The age of cancer. Nature.2000;408:248-254.
2. Doll R, Peto R. The causes of cancer: quantitative estimates
of avoidable risks of cancer in the United States today. J Natl
Cancer Inst. 1981;66:1191-1308.
3. Willett WC. Diet and cancer. Oncologist.2000;5:393-404.
4. Wu F, Wu Q. Corin-mediated processing of pro-atrial
natriuretic peptide in human small cell lung cancer cells. Cancer
Res. 2003;63:8318-8322.
5. Ohsaki Y, Gross AJ, Le PT, Oie H, Johnson BE. Human small
cell lung cancer cells produce brain natriuretic peptide.Oncology. 1999;56:155-159.
6. Popat J, Rivero A, Pratap P, Guglin M. What is causing
extremely elevated amino terminal brain natriuretic peptide in cancer
patients? Congest Heart Fail. 2013;19:143-148.
7. Tuñón J, Higueras J, Tarín N, et al. N-Terminal Pro-Brain
Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in
Patients with Coronary Artery Disease. PloS one.2015;10:e0126741-e0126741.
8. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte
chemoattractant protein-1 reduces atherosclerosis in low density
lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275-281.
9. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency
reduces susceptibility to atherosclerosis in mice that overexpress human
apolipoprotein B. J Clin Invest. 1999;103:773-778.
10. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic
value of galectin-3, a novel marker of fibrosis, in patients with
chronic heart failure: data from the DEAL-HF study. Clin Res
Cardiol. 2010;99:323-328.
11. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended
story. Biochim Biophys Acta. 2006;1760:616-635.
12. Omland T, Pfeffer MA, Solomon SD, et al. Prognostic value
of cardiac troponin I measured with a highly sensitive assay in patients
with stable coronary artery disease. J Am Coll Cardiol.2013;61:1240-1249.
13. Campbell PT, Gapstur SM, McCullough ML, et al. Circulating
Vitamin D and Colorectal Cancer Risk: An International Pooling Project
of 17 Cohorts. JNCI: Journal of the National Cancer Institute.2018;111:158-169.
14. Tunon J, Blanco-Colio L, Cristobal C, et al. Usefulness of
a combination of monocyte chemoattractant protein-1, galectin-3, and
N-terminal probrain natriuretic peptide to predict cardiovascular events
in patients with coronary artery disease. Am J Cardiol.2014;113:434-440.
15. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid
measurement of B-type natriuretic peptide in the emergency diagnosis of
heart failure. N Engl J Med. 2002;347:161-167.
16. Daniels LB, Maisel AS. Natriuretic peptides. J Am
Coll Cardiol. 2007;50:2357-2368.
17. Vaes B, de Ruijter W, Degryse J, Westendorp RG, Gussekloo
J. Clinical relevance of a raised plasma N-terminal pro-brain
natriuretic peptide level in a population-based cohort of nonagenarians.J Am Geriatr Soc. 2009;57:823-829.
18. Daniels LB, Laughlin GA, Clopton P, Maisel AS,
Barrett-Connor E. Minimally elevated cardiac troponin T and elevated
N-terminal pro-B-type natriuretic peptide predict mortality in older
adults: results from the Rancho Bernardo Study. J Am Coll
Cardiol. 2008;52:450-459.
19. Eggers KM, Venge P, Lind L. Prognostic usefulness of the
change in N-terminal pro B-type natriuretic peptide levels to predict
mortality in a single community cohort aged >/= 70 years.Am J Cardiol. 2013;111:131-136.
20. Barents M, Hillege HH, van der Horst IC, et al. BNP and
NT-proBNP, predictors of 1-year mortality in nursing home residents.J Am Med Dir Assoc. 2008;9:580-585.
21. Soualmia H, Ayadi I, Omar S, et al. Atrial natriuretic
peptide and brain natriuretic peptide release in human essential
hypertension. Clin Lab. 2009;55:120-127.
22. Knudsen CW, Omland T, Clopton P, et al. Impact of atrial
fibrillation on the diagnostic performance of B-type natriuretic peptide
concentration in dyspneic patients: an analysis from the breathing not
properly multinational study. J Am Coll Cardiol. 2005;46:838-844.
23. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal
pro-B-type natriuretic peptide after high-dose chemotherapy: a marker
predictive of cardiac dysfunction? Clin Chem. 2005;51:1405-1410.
24. Burjonroppa SC, Tong AT, Xiao LC, Johnson MM, Yusuf SW,
Lenihan DJ. Cancer patients with markedly elevated B-type natriuretic
peptide may not have volume overload. Am J Clin Oncol.2007;30:287-293.
25. Aujollet N, Meyer M, Cailliod R, et al. High N-terminal
pro-B-type natriuretic peptide: a biomarker of lung cancer? Clin
Lung Cancer. 2010;11:341-345.
26. Gimeno E, Gomez M, Gonzalez JR, et al. NT-proBNP: a cardiac
biomarker to assess prognosis in non-Hodgkin lymphoma. Leuk Res.2011;35:715-720.
27. Papazisis KT, Kontovinis LF, Papandreou CN, et al. Brain
natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical
benefit to sunitinib treatment in patients with metastatic renal cell
carcinoma. BMC Cancer. 2010;10:489.
28. Kamai T, Tokura Y, Uematsu T, et al. Elevated serum levels
of cardiovascular biomarkers are associated with progression of renal
cancer. Open Heart. 2018;5:e000666-e000666.
29. Pavo N, Raderer M, Hülsmann M, et al. Cardiovascular
biomarkers in patients with cancer and their association with all-cause
mortality. Heart. 2015;101:1874-1880.
30. Totsune K, Takahashi K, Murakami O, et al. Immunoreactive
brain natriuretic peptide in human adrenal glands and adrenal tumors.Eur J Endocrinol. 1996;135:352-356.
31. Kuwahara K, Nakao K. Regulation and significance of atrial
and brain natriuretic peptides as cardiac hormones. Endocr J.2010;57:555-565.
32. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal
transducer and activator of transcription 6 is frequently activated in
Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood.2002;99:618-626.
33. Biggar RJ, Johansen JS, Smedby KE, et al. Serum YKL-40 and
interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res.2008;14:6974-6978.
34. Niitsu N, Okamato M, Nakamine H, et al. Simultaneous
elevation of the serum concentrations of vascular endothelial growth
factor and interleukin-6 as independent predictors of prognosis in
aggressive non-Hodgkin’s lymphoma. Eur J Haematol.2002;68:91-100.
35. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R.
Serum interleukin-6 levels correlate with prognosis in diffuse
large-cell lymphoma. J Clin Oncol. 1995;13:575-582.
36. Pedersen LM, Jurgensen GW, Johnsen HE. Serum levels of
inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10
defined germinal centre (GC) phenotype and bcl-2 expression in patients
with diffuse large B-cell lymphoma. Br J Haematol.2005;128:813-819.
37. Vesely BA, Song S, Sanchez-Ramos J, et al. Five cardiac
hormones decrease the number of human small-cell lung cancer cells.Eur J Clin Invest. 2005;35:388-398.
38. Manimala NJ, Frost CD, Lane ML, Higuera M, Beg R, Vesely
DL. Cardiac hormones target nuclear oncogenes c-Fos and c-Jun in
carcinoma cells. Eur J Clin Invest. 2013;43:1156-1162.
39. Nguyen JP, Frost CD, Lane ML, Skelton Iv WP, Skelton M,
Vesely DL. Novel dual inhibitors of vascular endothelial growth factor
and VEGFR2 receptor. Eur J Clin Invest. 2012;42:1061-1067.
40. Zhang J, Zhao Z, Zu C, et al. Atrial natriuretic peptide
modulates the proliferation of human gastric cancer cells via KCNQ1
expression. Oncol Lett. 2013;6:407-414.
41. Zhang J, Zhao Z, Wang J. Natriuretic peptide receptor A as
a novel target for cancer. World J Surg Oncol. 2014;12:174.
42. Subramanian V, Vellaichamy E. Atrial natriuretic peptide
(ANP) inhibits DMBA/croton oil induced skin tumor growth by modulating
NF-kappaB, MMPs, and infiltrating mast cells in swiss albino mice.Eur J Pharmacol. 2014;740:388-397.